Advanced Search

    Technical Analysis for ACRS - Aclaris Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 13.73 -2.28% -0.32
    ACRS closed down 2.28 percent on Monday, February 6, 2023, on 2.55 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
    Earnings due: Feb 22
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical ACRS trend table...
    Date Alert Name Type % Chg
    Calm After Storm Range Contraction 0.00%
    NR7 Range Contraction 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    MACD Bearish Centerline Cross Bearish -2.28%
    Volume Surge Other -2.28%
    Stochastic Reached Oversold Weakness -2.28%
    Gapped Up Strength -2.28%
    Below Lower BB Weakness -2.28%
    Lower Bollinger Band Touch Weakness -2.28%
    Oversold Stochastic Weakness -2.28%
    Older End-of-Day Signals for ACRS ...

       Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

    Alert Time
    Possible NR7 about 3 hours ago
    60 Minute Opening Range Breakdown about 5 hours ago
    3x Volume Pace about 7 hours ago
    2x Volume Pace about 7 hours ago
    1.5x Volume Pace about 7 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators Basic chart:

    Profile

    Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology. Its lead drug candidate is A-101, a hydrogen peroxide topical solution that has completed three Phase II clinical trials for the treatment of seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101 as a prescription treatment for common warts; and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Malvern, Pennsylvania.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Pharmaceutical Chemical Substances Hydrogen Dermatology Stage Specialty Pharmaceutical Hydrogen Peroxide Topical Medication Common Warts Keratosis

    Is ACRS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jan 12 Aclaris Therapeutics (ACRS) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- Slideshow
    Jan 10 Aclaris Therapeutics Has Strong Upside Potential, But Shares Could Be Lower
    Jan 6 Aclaris Therapeutics Provides 2023 Outlook
    Dec 1 Goldman Sachs initiates Aclaris at Buy citing potential in lead asset
    Nov 29 Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China
    Nov 26 Lab Notes: Biotech firm bioMerieux unveils new product for detecting spoiled wine
    Nov 22 Aclaris Therapeutics names CEO as board chair, COO to take helm
    Nov 22 Aclaris Therapeutics Announces Key Leadership Transitions
    Nov 16 Aclaris Therapeutics Looks Promising on the Charts
    Nov 10 Aclaris Therapeutics to Participate in Two November Healthcare Investor Conferences
    See more ACRS news...

    Indicators

    Indicator Value
    52 Week High 18.9583
    52 Week Low 9.84
    Average Volume 427,309
    200-Day Moving Average 15.36
    50-Day Moving Average 16.05
    20-Day Moving Average 16.55
    10-Day Moving Average 16.03
    Average True Range 1.09
    RSI 31.97
    ADX 20.07
    +DI 15.95
    -DI 26.41
    Chandelier Exit (Long, 3 ATRs) 15.27
    Chandelier Exit (Short, 3 ATRs) 16.68
    Upper Bollinger Bands 18.85
    Lower Bollinger Band 14.25
    Percent B (%b) -0.11
    BandWidth 27.83
    MACD Line -0.35
    MACD Signal Line 0.04
    MACD Histogram -0.3884
    Fundamentals Value
    Market Cap 589.28 Million
    Num Shares 42.9 Million
    EPS -4.17
    Price-to-Earnings (P/E) Ratio -3.29
    Price-to-Sales 25.00
    Price-to-Book 3.76
    PEG Ratio -0.13
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 14.87
    Resistance 3 (R3) 14.89 14.53 14.68
    Resistance 2 (R2) 14.53 14.24 14.52 14.62
    Resistance 1 (R1) 14.13 14.06 13.95 14.11 14.55
    Pivot Point 13.77 13.77 13.68 13.76 13.77
    Support 1 (S1) 13.37 13.48 13.19 13.35 12.91
    Support 2 (S2) 13.01 13.30 13.00 12.84
    Support 3 (S3) 12.61 13.01 12.78
    Support 4 (S4) 12.59